HE homepage

DiA Imaging Analysis, an Israel-based healthcare technology company, has gained U.S. Food and Drug Administration (FDA) clearance for LVivo IQS, a new software solution designed to help users acquire high-quality echocardiography images.

The newly approved software uses artificial intelligence to provide users with real-time feedback related to image quality.

A heart team working together during a TAVR procedure at Emory. The success of the heart team approach has has made it a model for care collaborations across cardiovascular care.

Multidisciplinary heart teams are growing more and more popular among hospitals and health systems all over the world. What started as a way to select TAVR patients has become something much more important. 

Money dollar investments

In fact, 2022 was “easily” the second-best year for private equity healthcare services dealmaking, behind 2021.

A gavel and a stethoscope

Amazon announced its intent to acquire One Medical in July 2022, and the $3.9 billion deal came under fire right away, with critics voicing their concerns about Amazon’s growing size and reach.

An example of artificial intelligence (AI) automated detection of a intracranial hemorrhage (ICH) in. a CT scan used to send alerts to the stroke acute care team before a radiologist even sees the exam. Example shown by TeraRecon at RSNA 2022.

More than 500 clinical AI algorithms have now been cleared by the FDA, with the majority just in the past couple years.

Among general cardiologists, for example, median compensation jumped nearly 8% from 2023 to 2024. Interventional cardiology and electrophysiology saw even larger jumps. Dollar money graphic showing increased finance.

The company is pursuing treatments that could target diabetes and obesity in a pill form.

Around the web

The approval, made as part of a special FDA pilot program, took just 50 days.